International Journal on Science and Technology

E-ISSN: 2229-7677   •   Impact Factor: 9.88

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 16 Issue 2 April-June 2025 Submit your research before last 3 days of June to publish your research paper in the issue of April-June.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 16 Issue 2
April-June 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

RECENT ADVANCEMENTS IN PYRIDINE DERIVATIVES AS ANTICANCER AGENTS

Author(s) Saabirah Akhtar, Simran Tiwari, Suhail khan, Ravi Kumar, Dr, Nikul Gupta, Dr. Nakul Gupta
Country India
Abstract Pyridine derivatives are a structurally heterogeneous and pharmacologically important class of compounds with increasing importance in anticancer drug development. Their unique electronic profile, synthetic tractability, and high biological activity allow targeted modulation of critical molecular pathways implicated in cancer advancement. Recent developments are the discovery of pyridine-urea hybrids, fused heterocycles like pyrazolopyridines and thienopyridines, and hybrid pharmacophores, many of which have shown significant cytotoxicity against a broad spectrum of cancer cell lines with increased selectivity and fewer off-target effects. Mechanistic studies have shown their efficacy in inhibiting VEGFR-2- induced angiogenesis, HDAC inhibition, and tumor-associated enzyme-selective inhibition of human carbonic anhydrase IX and XII. These results have been buttressed by computational methods including molecular docking and SAR analysis, which enable rational drug design and optimization. Despite their promise, numerous challenges remain—such as systemic toxicity, poor selectivity, drug resistance, poor solubility, and synthesis complexity—that limit their clinical applicability. In an effort to overcome these challenges, scientists are investigating nanotechnology-based drug delivery systems, covalent inhibitor design, and environmentally friendly synthesis strategies for improving bioavailability and therapeutic index. Notable examples, including Linifanib and SLC-0111, have reached clinical trials, demonstrating the translational potential of this compound class. Further interdisciplinarity research to overcome current shortcomings will only serve to reinforce the position of pyridine derivatives in contemporary oncology as leading contenders for next-generation anticancer therapy.
Keywords pyridine derivatives, anticancer agent, drug resistance, nanotechnology
Field Chemistry > Pharmacy
Published In Volume 16, Issue 2, April-June 2025
Published On 2025-05-24
DOI https://doi.org/10.71097/IJSAT.v16.i2.5398
Short DOI https://doi.org/g9mq8b
View / Download PDF File

Share this


CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJSAT DOI prefix is
10.71097/IJSAT

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 15 Isu 4Cover Page Vol 15 Isu 3Cover Page Vol 15 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJSAT
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us Message on WhatsApp +91-9687-182-185 editor@ijsat.org